Bahaa Mustafa

Assistant professor

UAMS

Also affiliated: Arab Open University (2023); Arab Open University (2023); Winthrop Rockefeller Foundation (2025); University of Missouri–Kansas City (2021–2024)

Faculty Researcher

5 h-index 16 pubs 104 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Bahaa Mustafa's research focuses on developing novel therapeutic strategies for cancer immunotherapy, with a particular emphasis on targeting immune checkpoints. His work has involved the discovery and development of peptide-based inhibitors and domain antibodies that target Programmed Death-Ligand 1 (PD-L1), a key regulator of immune responses in the tumor microenvironment. Mustafa has also investigated the use of oncolytic viruses in combination with immune checkpoint blockade to enhance anti-tumor immunity in models of hepatocellular carcinoma and pancreatic cancer.

His research extends to the development of peptide-based inhibitors targeting ACE2 to inhibit SARS-CoV-2 infectivity, demonstrating a broader interest in peptide therapeutics. Mustafa has a publication record of 16 articles, with an h-index of 4 and 92 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences and Arkansas State University, including Mulu Z. Tesfay, Martin J. Cannon, Alexei G. Basnakian, and Khandoker Usran Ferdous.

Metrics

h-index: 5
Publications: 16
Citations: 104

Selected Publications

Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

Cancer Research DOI OpenAlex
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)

Cancer Research DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

Cancer Research DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

Molecular Therapy Oncology 5 citations DOI OpenAlex
Anti-CD47 Peptide Combined with Oncolytic Vesiculovirus-Driven Intratumoral Immunotherapy for Colorectal Cancer (2024)

American Journal of Pharmaceutical Education DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 5 citations DOI OpenAlex